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ABSTRACT
Chordoma is an extremely rare cancer, with an
incidence of about one case per million persons
per year in the USA and Europe (about 300 and
450 cases per year, respectively). The estimated
median overall survival of patients with
chordoma is approximately 6–7 years, yielding
a rough estimate of chordoma prevalence at
about 2000 in the USA and 3000 in Europe.
Primary tumor develops along the axial spine
between the clivus and sacrum and develops
from the residual embryonic notochord.
Brachyury (T), a transcription factor required
for normal embryonic development, is
expressed in the notochord and overexpressed
in almost all cases of chordoma. The primary
treatment for chordoma is surgical excision
with wide local margins, when possible.
Radiotherapy also plays a significant role in
the adjuvant setting and when surgery is not
possible. Unfortunately, in the advanced and/or
metastatic setting, where the role of surgery
and/or radiation is less clear, treatment options
are very limited. To date, there have been no
randomized, controlled trials in chordoma that
have resulted in defined agents of clinical
benefit for systemic treatment. This review
briefly describes the natural history and initial
treatment of chordoma and focuses on
treatment options for advanced disease and
potential avenues of research that may lead to
improved treatment options in the future.
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INTRODUCTION
Chordoma is an extremely rare cancer, with an
incidence of about one case per million persons
per year in the USA (about 300 cases per year)
[1]. Chordoma has been called ‘‘bone cancer’’
[2], but this designation is debatable based on
histologic features, which are more consistent
with its presumed tumor of origin, namely, the
residual embryonic notochord tissue [3, 4].
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Designating chordoma as a ‘‘bone tumor’’
appears to be a holdover from the initial
description of the disease by Virchow [5], but
it was called into question soon thereafter by
Ribbert [6], who coined the name ‘‘chordoma’’
based on its similarity to notochord tissue [7].
The relationship of chordoma to the notochord
was strengthened by the finding that brachyury,
a transcription factor found in notochord tissue
and essential for embryonic development, is
overexpressed in chordoma [3, 8]. Regardless of
its historical designation, chordoma has unique
histologic, radiographic, and clinical
characteristics that call for chordoma-specific
research to improve outcomes for patients with
the disease. In this review, I briefly review the
previously published natural history of the
disease, including tumor characteristics,
standard treatment paradigms, clinical
management issues, and results of systemic
treatment trials to date, to provide context for




Chordoma is most commonly diagnosed
between ages 50 and 60, and it is more
common in men than women, and rare in
children [1]. Primary tumors develop along the
axial spine, with approximately one-third of
cases presenting in the clivus, mobile spine, and
sacrum, respectively [1]. Disease presentation
depends on tumor location and is related to the
structures near which the tumor is growing. For
example, patients with clival chordomas may
present with headache, diplopia, or impairment
of other cranial nerves, while those with sacral
chordomas may present with low back or
buttocks pain, neuropathy, and/or gait
disturbance [7]. Patients may be diagnosed
with large tumor masses in the sacrum due to
the slow-growing nature of the disease,
non-specific symptom profile, and a relatively
large space for tumors to occupy before causing
significant focal symptoms. Imaging findings
that would point to chordoma include a mass
along the axial spine, likely invading
surrounding bone, which has a similar
intensity to surrounding tissue on T1-weighted
images, but appears hyperintense on
T2-weighted images [9, 10]. Unfortunately,
due to the slow-growing nature of chordoma,
which results in insidious, non-specific
symptoms, diagnosis may be delayed for
months or years. The median overall survival
(OS) from time of diagnosis has been estimated
at around 6 to 7 years [1], but the range of
outcomes is very wide and may be related to
prognostic markers, including treatment
options at the time of diagnosis [11–13], as
detailed below.
After surgical resection or initial biopsy, the
diagnosis of chordoma is confirmed based on
the classical (conventional) appearance of
‘‘sheets and cords of round to polygonal’’
tumor cells filled with occasionally large
mucin-filled eosinophilic cytoplasm called
physaliphorous cells [14]. Two less common
chordoma variants are chondroid chordoma
and dedifferentiated chordoma. Features of
chondroid chordoma include the presence of
‘‘cartilaginous differentiation, not present in
classical chordoma’’ [14]. Dedifferentiated
chordoma occurs in a small subset of patients
(\5%); it has an aggressive course and its
features are consistent with those of spindle
cell (sarcomatoid) carcinoma under histologic
review [15, 16]. In cases where the diagnosis is
not clear, staining for nuclear expression of
brachyury distinguishes chordoma from tumors
with similar morphologic features [8, 17, 18].
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TREATMENT AND INITIAL
PROGNOSIS
In 2015, the Chordoma Foundation and its
advisors published a global consensus based on
the input of world experts from the fields of
medical oncology, radiation oncology,
neurosurgery, and orthopedic surgery during
the 2013 European Society for Medical
Oncology annual meeting [19]. Practicing
clinicians should use these guidelines when
initially seeing a patient with chordoma, but
the importance of patients being seen by a
dedicated multidisciplinary team with
experience in this rare disease cannot be
overstated.
Surgery is the mainstay of treatment for
primary and/or recurrent chordoma when
feasible, and the outcome of surgery is closely
related to the expected outcome for a given
patient. Surgical techniques are specific to
tumor site, but in general, the goal is to
achieve a local excision with clear margins.
The surgical management of chordoma has
been discussed in detail in other recent
reviews [2, 7, 20] and thus will not be a focus
of this review. However, multiple retrospective
analyses have demonstrated the impact of
surgery on prognosis [21–23]. In clival
chordoma, though, there is evidence that
aggressive resection may actually be the more
cautious approach [13] because wide local
excision is commonly not an option [22].
Radiotherapy also plays a key role in the
management of patients with localized
chordoma, particularly in the adjuvant setting
after full resection or subtotal resection and as
the primary treatment in unresectable disease.
One series from Choy et al. indicated that the
use of adjuvant radiotherapy was the most
important variable influencing time to
progression [13]. A research group from
Massachusetts General Hospital demonstrated
excellent disease control with adjuvant
high-dose radiotherapy after surgery in
primary tumors after resection, but poor
outcomes in recurrent disease [12]. This group
went on to show reasonable tumor control with
high-dose proton or photon radiotherapy in
patients with primary, unresected chordoma,
with 5-year OS and local progression-free
survival (PFS) of 78.1% and 79.8%, respectively
[24]. The same group demonstrated very low
recurrence rates in patients with localized spinal
chordoma treated with high-dose radiotherapy,
with the exception of locally recurrent
chordomas, which had a 5-year recurrence rate
of 50% [25]. Because proton-beam therapy is
capable of delivering high doses of radiotherapy
to focal targets, it has advantages over photon
therapy. However, it is not clear that, at
equivalent doses, proton therapy has any
advantage over photon therapy in terms of
disease control or the likelihood of symptom
control.
Surgery, when feasible, should aim for
margin-negative resection without penetration
of the capsule, with adjuvant high-dose
radiotherapy for optimal local tumor control
[19]. Because this outcome is not possible for
most patients, prediction of clinical outcome is
very difficult for a given patient at the time of
initial management. Patients with residual
disease after surgery or unresectable disease at
the time of diagnosis should consider high-dose
radiotherapy at a center with expertise in
delivering such doses for chordoma. An
important surgical aspect of the tumor is
related to its histology. These tumors contain
gelatinous material that can spill into the
resection cavity even with careful planning,
and recurrence often occurs at the margins of
the resected tumor. These characteristics of
chordoma reinforce the importance of
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consulting an experienced, multidisciplinary
team for initial treatment. In fact, a recent
retrospective analysis suggested that
preoperative radiation may reduce the risk of
surgical-field contamination [26]. Patients
should be encouraged to seek the assistance of
advocacy groups, such as the Chordoma
Foundation (http://www.chordomafoundation.
org/), for recommendations of treatment
centers for their specific situation.
RECURRENT AND METASTATIC
DISEASE
Chordoma is often considered to be a
slow-growing disease with low metastatic
potential, but this description may give the
wrong impression of its disease course in the
advanced setting. Chambers et al. reported that
30% of patients developed metastatic disease,
with a predominance of lesions occurring in
patients with non-clival chordoma [27].
Kishimoto et al. described a similar incidence
of metastatic disease in a group of 198 patients
[9]. Other studies have described a wide range of
observed metastatic disease. However, it is
possible that these retrospective analyses
underrepresent the true incidence of
metastatic chordoma. Sites of metastatic
disease are widely variable and include
subcutaneous tissue, liver, lung, lymph nodes,
and bone [22, 27] (Fig. 1). Because some sites of
metastatic chordoma may not be well visualized
by an imaging modality that can easily detect
other sites of metastasis (Fig. 1), or because
clinical evaluation commonly focuses on local
recurrence, sites of metastatic disease can easily
be missed. However, this may not be an issue of
great significance in most cases because local
recurrence is still the major cause of morbidity
and mortality [22]. In older series, OS in
patients with metastatic disease has been
reported as approximately 1 year [28], but
more recent series have indicated a median OS
closer to 3 years [22, 29]. This apparent shift in
survival from the time of detection of
metastatic disease may be due to detection
bias, in which metastatic lesions are identified
earlier with improved imaging modalities and
more thorough evaluation. Alternatively, the
difference could be due to improved treatment
methods over time.
SYSTEMIC TREATMENT
To date, there has been no randomized,
controlled trial of a therapeutic agent in
locally advanced and/or metastatic chordoma.
Perhaps owing to the lack of clear historical
control data in this population, there also has
not been a study that has clearly defined
bFig. 1 Imaging of localized and metastatic chordoma
lesions. Imaging characteristics of chordoma lesions are
speciﬁc in variousmetastatic locations. In some cases, a lesion
may not be well visualized on computed tomography (CT)
images, but may be easily seen on magnetic resonance
imaging (MRI) scans, or vice versa. a Subcutaneous
metastatic lesion is reasonably well seen on contrast-en-
hanced CT (white arrow). b In a T2-weighted [(Short-TI
Inversion Recovery (STIR)] MRI sequence, the lesion glows
bright (white arrow) in contrast to surrounding tissue.
c Subcutaneous lesion is noted (white arrow, lower left), but
bone lesions are not well visualized (upper right).
d Subcutaneous lesion (white arrow, lower left) is easily
seen and bone invasion (white arrow, upper right) is also
readily visible. e Liver lesions (white arrow) appear very
similar to liver cysts in metastatic chordoma. f T2-weighted
(STIR) MRI images of the liver conﬁrm that the cystic-ap-
pearing lesion (white arrow) is consistent with chordoma.
g Lung lesions are easily seen on contrast-enhanced CT
(white arrow); little is gained from MRI scans of these same
lesions. h Primary tumor site in the lower spine or sacrum
(white arrow) can be difﬁcult to assess by CT due to similar
density of the lesion and surrounding tissue. I T2-weighted
(STIR) MRI images clearly delineate chordoma mass (white
arrow) from surrounding structures
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treatment benefit for patients with advanced
chordoma. The combination of the rarity of the
disease and the diversity of upfront clinical
management practice makes clinical trial design
and enrollment difficult. Table 1 summarizes
data from clinical trials of systemic treatment.
Imatinib is the most thoroughly evaluated
therapeutic agent in chordoma, based on the
expression of platelet-derived growth factor
beta (PDGFB) or its receptor (PDGFRB).
Imatinib, which is best known as an inhibitor
of the BCR-ABL gene fusion product, which is a
constitutively active tyrosine kinase, has
off-target effects, including the inhibition of
PDGFRB [30, 31]. In a single-arm phase II study,
Stacchiotti et al. observed a radiographic
response rate of only 1 of 50 patients (2%) as
measured by the Response Evaluation Criteria
in Solid Tumors (RECIST; 30% decrease in sum
of longest diameters), despite stable disease in
35 of 50 patients (70%). The median PFS in the
study was 9 months [32], but it is not clear how
this would compare with no treatment in a
similar cohort. In a separate retrospective
analysis, 17 of 17 patients with advanced
disease and PDGFR expression experienced
stable disease, but no radiographic responses
were observed [33]. Imatinib, though
commonly used in clinical practice [34], is not
approved by the U.S. Food and Drug
Administration (FDA), or by any other
regulatory agency, for the treatment of
chordoma.
Based on preclinical evidence of the role of
epidermal growth factor receptor (EGFR) in
chordoma pathogenesis [35], Stacchiotti et al.
performed a single-arm phase II clinical trial
evaluating lapatinib (a dual inhibitor of EGFR
and Her2) in subjects with advanced
EGFR-overexpressing chordomas. Eighteen
patients were enrolled and treated, and six
(33.3%) experienced a response based on the
Choi radiographic criteria. Median PFS in this
study was 6 months by the Choi criteria and
8 months by the RECIST guideline [36]. Further
attempts to target EGFR in chordoma include a
case report which described a radiographic
partial response using erlotinib alone [37], and
another case series which described
stable disease in three patients when erlotinib
was used in combination with bevacizumab
[38]. EGFR has also been targeted via the
combination of the monoclonal antibody
cetuximab and gefitinib, a tyrosine kinase
inhibitor of EGFR. In two separate case reports,
individual patients achieved partial
radiographically defined responses [39, 40].
Bompas et al. evaluated sorafenib, a
multikinase inhibitor, in an open-label,
multicenter, single-arm phase II clinical trial.
Sorafenib targets a number of tyrosine kinases
that are overexpressed in chordoma, including
vascular endothelial growth factor (VEGF),
PDGF, EGFR, and c-KIT [41]. The goal of the
study was to determine the 9-month PFS, as well
as to describe other clinical outcomes. After a
median 8.7-month follow-up, the median PFS
was not reached, median OS was not reached,
and there was one partial radiographic response
according to the RECIST 1.1 guideline. The
9-month PFS was 73%. Adverse events related to
sorafenib were similar to those seen historically
in other disease settings, which include grade 3
hand–foot syndrome (18.5%), diarrhea (18.5%),
hypertension (18.5%), weight loss (14.8%), and
fatigue (11.1%). Notably, there is no historical
control for trials such as this one in advanced
chordoma and due to the heterogeneity of the
patient population in the advanced setting, it is
difficult to interpret PFS in single-arm studies
like this. It is even more difficult to interpret PFS
in the setting of significant toxicities, such as
those caused by sorafenib. In the opinion of this
author, the radiographic response is interesting
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and deserves further study, but any future study
should have an active comparator arm to
determine the role of sorafenib, given its
adverse-event profile.
A single-arm phase II study of
9-nitro-camptothecin, an oral topoisomerase I
inhibitor, enrolled 15 patients with advanced
chordoma. One of 15 patients (7%) had an
objective radiographic response, and the
median PFS was 9.9 months [43]. Thalidomide
has also been reported to induce a radiographic
response in one case report [44]. Despite





Reported results Study design References
Imatinib PDGFR 50 1 PR (RECIST); 35 SD;






Imatinib PDGFR 17 0 PR; 17 SD Case series Ferraresi et al.
[33]
Lapatinib EGFR 18 13 SD; 6 PR (Choi); 0 PR
(RECIST); median






Erlotinib EGFR 1 1 PR Case report Singhal et al.
[37]
Erlotinib ? bevacizumab EGFR, VEGF 3 3 SD Case report Asklund et a.
[38]
Cetuximab ? geﬁtinib EGFR 1 1 PR Case report Hof et al. [39]
Cetuximab ? geﬁtinib EGFR 1 1 PR Case report Linden et al.
[40]
Sorafenib Multiple 27 1 PR (RECIST); 9-month
PFS = 73.0%;







15 1 PR (RECIST); median










Brachyury 11 1 PR (RECIST); 1 mixed
response (RECIST);
median
PFS = 8.3 months
Phase I trial Heery et al.
[65]
Table is modiﬁed with permission from http://www.chordomafoundation.org/systemic-therapy/
PR partial response, PFS progression-free survival, RECIST Response Evaluation Criteria in Solid Tumors, SD stable disease
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intermittent reports of activity with various
agents, there is no clear standard of treatment
in the advanced disease setting.
It is unclear if the agents described herein
have an impact on clinical outcomes in patients
other than those who have responses, because
there is no clear historical control or randomized
control arm comparator for PFS in the single-arm
studies performed to date. The heterogeneity of
clinical outcomes in the advanced disease
setting, paired with the rarity of the disease,
makes the path to drug registration unclear
unless an agent induces objective responses in a
larger proportion of patients [45].
POTENTIAL FUTURE TREATMENTS
Brachyury
In addition to being a diagnostic marker for
chordoma, brachyury may be a potential target
for treatment [46, 47]. Brachyury appears to be
an oncogenic driver of chordoma [3, 48]. The
non-synonymous presence of the rs2305086
single nucleotide polymorphism was
associated with increased risk of chordoma in
one series [49], yet in another study, in Chinese
patients, no such association was found [50].
It was previously thought that brachyury was
specific only to chordoma and could be used,
primarily, as a diagnostic tool [8, 51]. While
nuclear brachyury expression remains useful to
distinguish chordoma from tumors with similar
morphologic features, it has become clear that
brachyury is also expressed in other tumors,
including epithelial tumors [34, 52–55]. Our
group has developed a rabbit monoclonal
antibody [56] that is highly specific for
brachyury staining. In a recent analysis of
[5000 tumors, nuclear brachyury expression
was present in [98% of chordomas analyzed
[17]. This study only evaluated nuclear staining
and did not analyze cytosolic expression of
brachyury, as has been described in other
tumors [56].
In epithelial tumors, brachyury expression
drives epithelial-to-mesenchymal transition,
inducing stem-like features such as migration,
invasiveness, and resistance to conventional
therapy [57–59]. In retrospective analyses of
cohorts of patients with prostate [52], colorectal
[53], breast [54], lung [55], and hepatocellular
carcinoma [34], brachyury expression has been
associated with poor prognosis. Interestingly,
chordoma cells express many of the markers of
mesenchymal cells typically induced with
brachyury upregulation in other tumor types,
including decreased e-cadherin levels and
increasedn-cadherin[60]andvimentin levels [61].
Historically, transcription factors have been
considered ‘‘undruggable’’ [62] with targeted or
standard cytotoxic agents, but other potential
avenues for targeting brachyury have been
proposed, including small inhibitory RNA,
epigenetic modulation, and immune-based
therapy [63, 64]. To date, the only attempts to
target brachyury have been with two
therapeutic cancer vaccines. Our group
recently completed a phase I trial of GI-6301
(recombinant yeast-brachyury vaccine) which
enrolled 11 patients with advanced chordoma
(NCT01519817) [65]. One patient had a
confirmed radiographic partial response (PR)
by the RECIST guideline, and a second had a
mixed response; the median PFS in the
chordoma group was 8.3 months. The vaccine
induced brachyury-specific T cell responses in
both the majority of all patients enrolled and
the subset of patients enrolled with chordoma.
There were no significant toxicities related to
the vaccine [65]. Notably, the two patients with
evidence of tumor shrinkage both had
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radiotherapy within 3.5 months of being
enrolled on study. Given the low likelihood of
radiographic response with radiotherapy alone
in the advanced disease setting, our hypothesis
was an immunomodulatory effect of
radiotherapy on chordoma cells which
resulted in an increased responsiveness to T
cell-mediated killing. Hodge et al. described a
similar effect in other tumor cell lines [66–68].
Another phase I study of a vaccine targeting
brachyury has recently completed accrual
(NCT02179515). This vaccine is composed of a
modified vaccinia virus Ankara (MVA) vector
containing the transgene for brachyury and
three costimulatory molecules (designated
TRICOM).
Mucin 1 and Carcinoembryonic Antigen
A majority of chordoma cases from historical
series express mucin 1 [MUC1 or epithelial
membrane antigen (EMA)] [61].
Immunohistochemistry (IHC) studies have also
identified carcinoembryonic antigen on
chordoma cells in a lower percentage (3 of 14,
21%) of cases [61]. Both of these targets can also
be targeted immunologically with therapeutic
cancer vaccines [69, 70] and may be candidates
for future clinical trials.
Survivin
Survivin is another protein associated with poor
prognosis and metastatic potential in other
tumor types [71–76]. It is a member of the
inhibitor of apoptosis (IAP) gene family. Similar
to brachyury, it is rarely or never expressed in
normal adult tissue, but it is found in many
tumor cell types, including lung, colon, breast,
prostate, and pancreatic cancer cells [77]. Chen
et al. first described survivin expression in 21 of
30 (70%) sacral chordoma samples analyzed by
IHC. Interestingly, these authors identified an
association between survivin expression, which
was mainly cytoplasmic, and the likelihood of
both recurrence and local invasion at the time
of surgery. Survivin did not correlate with any
other demographic variable analyzed in that
study [78].
Froehlich et al. then explored the function of
survivin in chordoma cells [79] and evaluated
survivin expression in 50 chordoma cases (34
primary and 16 recurrent) from 44 patients
using IHC. Twenty-three of 34 (68%) primary
chordoma cases and 16 of 16 recurrent
chordomas stained positive. Interestingly, of
the positive-staining primary cases, only one
had nuclear expression (others only had
cytoplasmic staining), but all cases of recurrent
chordoma were positive for nuclear staining.
Three of three chordoma cell lines showed
nuclear and cytoplasmic staining. There was
no relationship between survivin expression
and any of the demographic variables tested.
The investigators then silenced survivin in the
chordoma cell line using YM155 (sepantronium
bromide), a survivin inhibitor. The treatment
reduced survivin protein expression and
increased markers of apoptosis. Based on their
findings, the authors suggested that YM155,
which has been demonstrated to be safe in
other diseases [80–82], could be a potential
therapeutic agent for use in chordoma [79].
MicroRNA-Focused Approaches
MicroRNAs (miRNAs) are small, noncoding,
single-stranded segments of endogenous RNA,
19–25 nucleotides in length, that are capable of
controlling gene expression through binding
and thus preventing messenger RNA (mRNA)
translation [83]. Because these segments of
miRNA are not translated directly into protein,
their role is mainly to regulate the expression of
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mRNA. It has been hypothesized that miRNA
may have an important role in the
dysregulation that occurs in human cancers;
consequently, the manipulation of miRNAs
may become a therapeutic intervention in the
future. In recent years, many groups have
investigated the potential role of miRNA in
chordoma, and some interesting patterns of
expression have emerged. A number of research
groups have taken additional steps to
demonstrate that increasing or decreasing
certain miRNAs can have downstream effects
on the expression of gene products thought to
be important in the growth and progression of
chordoma.
Duan et al. published the results of an initial
study in which they evaluated and compared
the expression of miRNA in human chordoma
tissue samples and chordoma cell lines to that
in normal tissues [84]. These authors found
similar expression profiles of miRNA in
chordoma cell lines and chordoma tissue
samples. Additionally, 21 miRNA genes were
differentially expressed between normal human
tissue and the chordoma cell lines and
chordoma tissue samples, including decreased
expression of miRNA-1 and miRNA-206. Of
these findings, perhaps the most interesting is
the decreased expression of miRNA-1 in
chordoma tissue and cell lines, which is a
pattern seen in other sarcomas and epithelial
malignancies. The authors also observed
overexpression of Met and HDAC4 in the
miRNA-1-deficient chordoma cells and tissue
and went on to demonstrate that transfection of
cell lines with miRNA-1 could suppress Met
expression and decrease chordoma cell
proliferation in vitro, leading them to suggest
that miRNA-1 could be a candidate for
therapeutic intervention in the future [84].
Later work by the same group confirmed that
miRNA-1 is downregulated in 93.7% of
chordoma tissues and has an inverse
correlation with Met expression [85], which
appears to occur downstream through control
of the Slug gene in chordoma cells [86].
In a similar study, Long et al. evaluated the
differential expression of miRNA and mRNA in
chordoma versus notochord tissues [87]. Their
microarray analysis identified differential
expression of 33 miRNAs and 2791 mRNAs.
Interestingly, 911 mRNAs were connected to
signaling pathways regulated by miRNAs. These
investigators found that the mitogen-activated
protein kinases (MAPK) pathway was
augmented in the chordoma tissue, which
may have been influenced by suppressed
expression of regulator miRNA associated with
this pathway, including miRNA-149-3p,
miRNA-663a, miRNA-1908, miRNA-2861, and
miRNA-3185. In addition to the MAPK
pathway, a number of other signaling
pathways were found to be upregulated in
chordoma, including those of transforming
growth factor beta (TGFb), Wnt, p53, ErbB,
Notch, Jak-STAT, T-cell receptor signaling,
mechanistic target of rapamycin (mTOR), and
gonadotropin-releasing hormone (GnRH),
among others. Perhaps most notably, six genes
associated with Notch signaling were
upregulated, indicating that this may be a
pathway of interest for therapeutic
intervention in future studies. Finally, the
authors identified a link to suppressed miRNAs
(miRNA-1228, miRNA-2861, miRNA-762) and
pathway expression of genes related to
ossification, which may be another potential
therapeutic target in the future.
Further work by other groups has identified a
number of potentially important differential
expression patterns of miRNA in chordoma
relative to normal tissue. These include
mRNA-31, which has an apoptotic effect on
chordoma cells by downregulating the
44 Oncol Ther (2016) 4:35–51
expression of c-MET and radixin [88],
miRNA-608 and miRNA-34a, which regulate
EGFR, MET, and Bcl-xL [89], miRNA-10a and
miRNA-125a, which were associated with
adenosine deaminase acting on RNA
expression [90], and miRNA-140-3p [91],
miRNA-155 [92], and miRNA-1237-3p [93],
which appear to be indicators of poor
prognosis in retrospective analyses of
chordoma samples.
The clinical utility of miRNA as a therapeutic
target will depend heavily on the identification
of a reliable delivery mechanism to tumor tissue
in patients.
Immune Checkpoint Inhibition
Part of the complicated interaction between the
immune system and tumor cells includes a
normally occurring feedback loop thought to
play a role in preventing autoimmunity. When
a T cell is activated against an antigen, it
upregulates programmed cell death receptor-1
(PD-1) and begins to secrete type 1 cytokines,
including interferon-gamma (IFN-c). In
response to the cytokine secretion of activated
T cells, normal human tissue will respond (via
IFN-c receptor signaling) by upregulating
programmed cell death ligand-1 (PD-L1). The
binding of PD-L1 to PD-1 completes a feedback
loop which causes suppression of the activated
T cell, thereby preventing T cell-mediated
damage of normal human cells and,
consequently, autoimmunity. In many
cancers, tumor cells also employ this system,
which prevents T cell-mediated killing of tumor
cells, even when an active immune response is
present against the tumor. Blockade of this
interaction with monoclonal antibodies
designed to bind to PD-1 or PD-L1 has proven
to be an effective antitumor strategy in a subset
of patients with many different tumors [94–97].
A natural question is whether this strategy
might be useful in the systemic treatment of
advanced chordoma.
Two analyses of PD-L1 expression by groups
at Johns Hopkins and Mass General,
respectively, found slightly different
expression patterns. The researchers at Johns
Hopkins found that three of the six cases
studied had infiltrating lymphocytes with
PD-1 expression within the tumor lesion, but
they did not find any tumor cells expressing
PD-L1. However, they did find PD-L1 expression
on tumor-infiltrating macrophages and
tumor-infiltrating lymphocytes [98]. In
contrast, the researchers at Mass General
found PD-L1 expression in nine human tissue
samples, but were unclear which cells expressed
PD-L1, making the results somewhat more
difficult to interpret [99]. In chordoma cell
lines, both groups observed that PD-L1
expression can be induced in response to IFN-c
or other pro-inflammatory cytokines. This
finding indicates that the generation of an
active immune response against chordoma
in vivo (for example, via vaccine) could be
complemented with PD-1/L1 inhibition,




(MGMT) promoter methylation status in
chordoma was reported for the first time in a
recent publication by Marucci et al. [100] These
authors observed MGMT promoter
methylation, which is known to predict the
efficacy of temozolomide in glioblastoma, in
four of 15 (27%) cases of recurrent clival
chordoma. The MGMT promotor was not
methylated in any of 15 patients with clival
chordoma who did not have a recurrence after a
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median follow-up of 8.5 years. Based on these
findings, the authors suggest that patients with
MGMT promotor methylation at the time of
surgery could be considered for temozolomide
therapy on the basis of its increased efficacy in
glioblastoma when MGMT promotor
methylation is present [101].
Histone Deacetylase Inhibition
Lee et al. recently demonstrated the potential
role of histone deacetylase inhibition (HDACi)
to overcome resistance to PDGFR inhibition
mediated by the loss of heterozygosity of
phosphatase and tensin homolog (PTEN).
Indeed, in their study it appeared that HDACi
diminished the aggressive phenotype seen in
tumor cells with aberrant PTEN expression
[102]. Other groups have suggested that
HDACi may play a role in epigenetic
modulation [103–105]. Given the significant
role of the transcription factor brachyury in
chordoma, agents like HDACi could potentially
have an indirect effect on gene expression via
epigenetic modulation. This is an area that
should be explored in future clinical trials.
Hypofractionated Radiotherapy
Yamada et al. have pioneered the use of
hypofractionated radiotherapy for chordoma,
first showing that it was feasible [106] and then
evaluating its efficacy [107]. Of 24 treated
patients enrolled in their study, 23 (95%)
showed evidence of clinical benefit
(stable disease or tumor shrinkage) on serial
imaging. The greatest benefit was seen when a
high-dose single fraction was delivered to a
primary tumor. However, disease control has
also been accomplished with multiple fractions
at slightly lower doses in primary and recurrent
tumors [106].
CONCLUSIONS
The initial management of chordoma is fairly well
defined. Patients should have maximal tumor
debulking and adjuvant high-dose radiotherapy
when possible. When surgery is not possible,
high-dose radiotherapy achieves reasonable
disease control in most cases. However, the
majority of patients are not eligible for optimal
therapy, and most of these will have disease
recurrence. In most cases, recurrent disease will
lead to death along variable timelines. As a result,
there is an urgent need for therapeutic options
capable of controlling or shrinking tumors. To
date, evaluations of systemic therapies have been
limited to single-arm studies or case reports.
Unfortunately, despite rational selection of
agents based on potential therapeutic targets
identified by extensive preclinical work,
radiographic response rates have been very low.
Thus, the impact of these agents cannot be fully
assessed, which has precluded their approval for
use in advanced chordoma by the FDA or other
regulatory agencies. Additional therapeutic
targets continue to emerge, including brachyury,
survivin, and others not described here. The
recent activity seen in other tumor types treated
with immunotherapy suggests that therapeutic
cancer vaccines, immune checkpoint inhibitors,
or a combination of these agents may be potential
therapeutic options for chordoma. Careful
selection of patient populations and endpoints
will be required to definitively demonstrate
efficacy and increase the armamentarium for
physicians treating this rare tumor.
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